Advanced search×

Futile treatment and the ethics of medicine.

Nancy S NS Jecker

Rep Inst Philos Public Policy 15(1):10-4 (1995) PMID 11652934

Version: za2963e q8za6 q8zb0 q8zc0 q8zd4 q8zee q8zfb q8zgd
PDF not found

Similar articles you may find interesting…

  1. The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives.
    Xi-Mei Wang, Yue-Jin Yang, and Yong-Jian Wu

    Cardiovasc Drugs Ther (2013) PMID 23645229

    We summarize the available data on cardiovascular protection by DPP-4 inhibitors that have emerged in recent years and discuss current position and future perspectives concerning the use of DPP-4 inhibitors in cardiovascular medicine....
  2. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult pat...
    S R Lentz, M Misgav, and U Martinowitz

    Haemophilia (2013) PMID 23647704

    Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in patients with severe haemophilia A. This multinational, open-label, non-controlled trial investigated the safety and efficacy of turoctoc...
  3. Initial Outcome After Selective Intraarterial Radionuclide Therapy with Yttrium-90 Microspheres as Salvage Therapy for Unresectable Metastat...
    Cuneyt Turkmen, Adem Ucar, and Isik Adalet

    Cancer Biother Radiopharm (2013) PMID 23647219

    Of the 61 patients, 32 were alive at the end of the study; median overall survival (OS) was 17.0±2.5 months (95% confidence interval: 11.9-22.0). A subset analysis of colorectal and noncolorectal groups demonstrated median OS rates of 14.0±5.8 and 17.0±4.8 months, respectively (p=0.543). The mean...